Contrasting NantHealth (NH) & Its Peers
NantHealth (NYSE: NH) is one of 21 publicly-traded companies in the “Medical Software & Technology Services” industry, but how does it contrast to its rivals? We will compare NantHealth to related businesses based on the strength of its risk, institutional ownership, dividends, valuation, analyst recommendations, earnings and profitability.
This table compares NantHealth and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations and price targets for NantHealth and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
NantHealth presently has a consensus price target of $9.25, indicating a potential upside of 174.48%. As a group, “Medical Software & Technology Services” companies have a potential upside of 20.98%. Given NantHealth’s stronger consensus rating and higher probable upside, analysts plainly believe NantHealth is more favorable than its rivals.
Institutional and Insider Ownership
64.6% of shares of all “Medical Software & Technology Services” companies are held by institutional investors. 21.9% of shares of all “Medical Software & Technology Services” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares NantHealth and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|NantHealth Competitors||$422.43 million||-$16.79 million||372.35|
NantHealth’s rivals have higher revenue, but lower earnings than NantHealth. NantHealth is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
NantHealth rivals beat NantHealth on 7 of the 10 factors compared.
NantHealth, Inc. is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples. The Company also offers Nant Operating System (NantOS) and NantOS applications to healthcare providers and payors, self-insured employers and biopharmaceutical companies. It offers CLINICS, an integrated solution that includes GPS Cancer, NantOS and the NantOS applications. The CLINICS solution includes System Infrastructure, Knowledge Platform, Provider Platform and Payor Platform.
Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.